ChemoCentryx Inc (NASDAQ:CCXI) was the recipient of a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 3,208,000 shares, a growth of 52.3% from the May 30th total of 2,106,800 shares. Based on an average trading volume of 523,500 shares, the short-interest ratio is currently 6.1 days. Approximately 10.5% of the shares of the stock are short sold.
CCXI stock traded down $0.19 during trading on Thursday, hitting $8.67. The stock had a trading volume of 201,100 shares, compared to its average volume of 497,534. The company has a debt-to-equity ratio of 0.24, a current ratio of 3.43 and a quick ratio of 3.43. ChemoCentryx has a twelve month low of $8.06 and a twelve month high of $14.98. The stock has a market cap of $516.63 million, a PE ratio of -11.41 and a beta of 1.11. The business’s 50-day moving average price is $9.50.
ChemoCentryx (NASDAQ:CCXI) last posted its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.01. ChemoCentryx had a negative return on equity of 111.15% and a negative net margin of 97.22%. The company had revenue of $8.33 million for the quarter, compared to analysts’ expectations of $11.37 million. As a group, equities analysts anticipate that ChemoCentryx will post -0.92 earnings per share for the current fiscal year.
A number of research firms have recently commented on CCXI. TheStreet upgraded Patrick Industries from a “c+” rating to a “b-” rating in a research report on Monday, March 18th. B. Riley began coverage on Victory Capital in a research report on Wednesday, March 27th. They set a “buy” rating and a $20.00 target price on the stock. Zacks Investment Research upgraded HANNOVER RUECK/S from a “sell” rating to a “hold” rating in a research report on Friday, May 17th. Canaccord Genuity restated a “buy” rating and set a GBX 285 ($3.72) target price on shares of in a research report on Thursday, June 6th. Finally, BidaskClub cut Virtu Financial from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 12th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $17.71.
In other news, SVP Rajinder Singh sold 33,000 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $12.96, for a total transaction of $427,680.00. Following the sale, the senior vice president now directly owns 43,614 shares in the company, valued at approximately $565,237.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Geoffrey M. Parker sold 12,815 shares of the firm’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $12.00, for a total value of $153,780.00. Following the sale, the director now owns 85,014 shares in the company, valued at $1,020,168. The disclosure for this sale can be found here. 12.20% of the stock is owned by company insiders.
A number of hedge funds have recently bought and sold shares of CCXI. FMR LLC boosted its holdings in ChemoCentryx by 796.2% in the 1st quarter. FMR LLC now owns 5,774,432 shares of the biopharmaceutical company’s stock worth $80,207,000 after buying an additional 5,130,127 shares during the last quarter. Wasatch Advisors Inc. boosted its holdings in ChemoCentryx by 6.1% in the 1st quarter. Wasatch Advisors Inc. now owns 2,464,664 shares of the biopharmaceutical company’s stock worth $34,234,000 after buying an additional 141,341 shares during the last quarter. Marshall Wace LLP acquired a new stake in ChemoCentryx in the 1st quarter worth about $1,840,000. Dimensional Fund Advisors LP boosted its holdings in ChemoCentryx by 15.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 632,061 shares of the biopharmaceutical company’s stock worth $6,896,000 after buying an additional 84,290 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in ChemoCentryx by 33.0% in the 4th quarter. Geode Capital Management LLC now owns 333,917 shares of the biopharmaceutical company’s stock worth $3,642,000 after buying an additional 82,918 shares during the last quarter. Institutional investors own 58.14% of the company’s stock.
ChemoCentryx Company Profile
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.
Read More: Put Option
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.